Cassava Sciences | PTIE - Cost Of Sales


Cassava Sciences reported $3.96M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Biogen USD 797.5M 302M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cassava Sciences USD 3.96M 1.16M Sep/2025
Eisai JPY 52.02B 931M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Geron USD 1.69M 386K Mar/2026
J&J USD 8.07B 103M Mar/2026
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 4.59B 1.7B Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025